Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 276

1.

Sildenafil citrate therapy for pulmonary arterial hypertension.

Galiè N, Ghofrani HA, Torbicki A, Barst RJ, Rubin LJ, Badesch D, Fleming T, Parpia T, Burgess G, Branzi A, Grimminger F, Kurzyna M, Simonneau G; Sildenafil Use in Pulmonary Arterial Hypertension (SUPER) Study Group.

N Engl J Med. 2005 Nov 17;353(20):2148-57. Erratum in: N Engl J Med. 2006 Jun 1;354(22):2400-1.

2.

Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial.

Simonneau G, Rubin LJ, Galiè N, Barst RJ, Fleming TR, Frost AE, Engel PJ, Kramer MR, Burgess G, Collings L, Cossons N, Sitbon O, Badesch DB; PACES Study Group.

Ann Intern Med. 2008 Oct 21;149(8):521-30. Erratum in: Ann Intern Med. 2009 Jan 6;150(1):63. Ann Intern Med. 2009 Sep 15;151(6):435.

PMID:
18936500
3.
4.

The efficacy and tolerability of sildenafil in patients with moderate-to-severe pulmonary hypertension.

Bharani A, Mathew V, Sahu A, Lunia B.

Indian Heart J. 2003 Jan-Feb;55(1):55-9.

PMID:
12760589
5.

Sildenafil improves exercise capacity and quality of life in patients with systolic heart failure and secondary pulmonary hypertension.

Lewis GD, Shah R, Shahzad K, Camuso JM, Pappagianopoulos PP, Hung J, Tawakol A, Gerszten RE, Systrom DM, Bloch KD, Semigran MJ.

Circulation. 2007 Oct 2;116(14):1555-62. Epub 2007 Sep 4.

6.

Long-term treatment with oral sildenafil is safe and improves functional capacity and hemodynamics in patients with pulmonary arterial hypertension.

Michelakis ED, Tymchak W, Noga M, Webster L, Wu XC, Lien D, Wang SH, Modry D, Archer SL.

Circulation. 2003 Oct 28;108(17):2066-9. Epub 2003 Oct 20.

7.

Oral sildenafil in the treatment of erectile dysfunction. Sildenafil Study Group.

Goldstein I, Lue TF, Padma-Nathan H, Rosen RC, Steers WD, Wicker PA.

N Engl J Med. 1998 May 14;338(20):1397-404. Erratum in: N Engl J Med 1998 Jul 2;339(1):59.

8.
9.

Sildenafil for pulmonary arterial hypertension associated with connective tissue disease.

Badesch DB, Hill NS, Burgess G, Rubin LJ, Barst RJ, Galiè N, Simonneau G; SUPER Study Group.

J Rheumatol. 2007 Dec;34(12):2417-22. Epub 2007 Nov 1.

PMID:
17985403
10.

Oral sildenafil as long-term adjunct therapy to inhaled iloprost in severe pulmonary arterial hypertension.

Ghofrani HA, Rose F, Schermuly RT, Olschewski H, Wiedemann R, Kreckel A, Weissmann N, Ghofrani S, Enke B, Seeger W, Grimminger F.

J Am Coll Cardiol. 2003 Jul 2;42(1):158-64.

11.

A randomized, double-blind, placebo-controlled, dose-ranging study of oral sildenafil citrate in treatment-naive children with pulmonary arterial hypertension.

Barst RJ, Ivy DD, Gaitan G, Szatmari A, Rudzinski A, Garcia AE, Sastry BK, Pulido T, Layton GR, Serdarevic-Pehar M, Wessel DL.

Circulation. 2012 Jan 17;125(2):324-34. doi: 10.1161/CIRCULATIONAHA.110.016667. Epub 2011 Nov 29.

12.

Sildenafil increased exercise capacity during hypoxia at low altitudes and at Mount Everest base camp: a randomized, double-blind, placebo-controlled crossover trial.

Ghofrani HA, Reichenberger F, Kohstall MG, Mrosek EH, Seeger T, Olschewski H, Seeger W, Grimminger F.

Ann Intern Med. 2004 Aug 3;141(3):169-77.

PMID:
15289213
13.

Efficacy and safety of sildenafil added to treprostinil in pulmonary hypertension.

Gomberg-Maitland M, McLaughlin V, Gulati M, Rich S.

Am J Cardiol. 2005 Nov 1;96(9):1334-6. Epub 2005 Sep 16.

PMID:
16253609
14.

Sildenafil for primary and secondary pulmonary hypertension.

Watanabe H, Ohashi K, Takeuchi K, Yamashita K, Yokoyama T, Tran QK, Satoh H, Terada H, Ohashi H, Hayashi H.

Clin Pharmacol Ther. 2002 May;71(5):398-402.

PMID:
12011826
15.

[Efficacy of oral sildenafil as rescue therapy in patients with severe pulmonary arterial hypertension chronically treated with prostacyclin. Long-term results].

Jiménez López-Guarch C, Escribano Subias P, Tello de Meneses R, Delgado Jiménez JF, Sadia Pérez D, Velázquez Martín MT, Gómez Sánchez MA, Sáenz de la Calzada C.

Rev Esp Cardiol. 2004 Oct;57(10):946-51. Spanish.

16.

Safety and efficacy of transition from subcutaneous treprostinil to oral sildenafil in patients with pulmonary arterial hypertension.

Keogh AM, Jabbour A, Weintraub R, Brown K, Hayward CS, Macdonald PS.

J Heart Lung Transplant. 2007 Nov;26(11):1079-83. Epub 2007 Oct 24.

PMID:
18022071
17.

Combination therapy with oral sildenafil and inhaled iloprost for severe pulmonary hypertension.

Ghofrani HA, Wiedemann R, Rose F, Olschewski H, Schermuly RT, Weissmann N, Seeger W, Grimminger F.

Ann Intern Med. 2002 Apr 2;136(7):515-22.

PMID:
11926786
18.

Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension: comparison with inhaled nitric oxide.

Michelakis E, Tymchak W, Lien D, Webster L, Hashimoto K, Archer S.

Circulation. 2002 May 21;105(20):2398-403.

19.

A potential role for sildenafil in the management of pulmonary hypertension in patients with parenchymal lung disease.

Madden BP, Allenby M, Loke TK, Sheth A.

Vascul Pharmacol. 2006 May;44(5):372-6. Epub 2006 Mar 29.

PMID:
16574495
20.

Safety and efficacy of Sildenafil therapy in children with pulmonary hypertension.

Karatza AA, Bush A, Magee AG.

Int J Cardiol. 2005 Apr 20;100(2):267-73.

PMID:
15823634

Supplemental Content

Support Center